Skip to main content
main-content

Oncology

Editor's pick

Direct oral anticoagulants AVERT VTE events in patients with cancer

Blood clot

The results of the randomized CASSINI and AVERT trials support the prophylactic use of the direct oral anticoagulants rivaroxaban and apixaban in cancer patients undergoing chemotherapy who are at risk for venous thromboembolism events.

Editor's pick

Durable response to tisagenlecleucel shown in DLBCL

IV drip

Heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma respond well to treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel, show results of the pivotal JULIET trial.

Editor's pick

Multiparametric MRI does not render systematic prostate biopsy obsolete

Man in scanner

Pre-biopsy multiparametric magnetic resonance imaging improves the detection of clinically significant prostate cancer in biopsy-naive patients but does not appear to remove the need for systematic biopsy, MRI-FIRST study data show.

SABCS 2018: PD-L1 in immune cells predicts atezolizumab plus nab-paclitaxel efficacy in metastatic triple-negative breast cancer

Presenting author Leisha Emens outlines exploratory efficacy analysis results from IMpassion130 showing that programmed cell death ligand 1 in immune cells is a robust predictive biomarker for selecting women with metastatic triple-negative breast cancer who may benefit from first-line atezolizumab plus nab-paclitaxel treatment (6:19).

SABCS 2018: Circulating tumour cell count could aid first-line hormone versus chemotherapy treatment decisions

Francois-Clement Bidard reports findings that circulating tumour cell count could help oncologists choose between first line hormone therapy and chemotherapy in women with oestrogen receptor positive, HER2-negative metastatic breast cancer (3:23).

SABCS 2018: Achieving pCR after neoadjuvant chemotherapy improves event-free and overall survival

Aditya Bardia explains the importance of research done by him and his colleagues validating pCR as a robust surrogate biomarker for outcomes particularly in women with triple negative and HER2-positive breast cancer (5:26).  

SABCS 2018: Impact of breast cancer surgery on quality of life

Ann Partridge discusses the E5103 study findings regarding the quality of life issues faced by women undergoing mastectomy and the need to continue monitoring them long term (5:14).

SABCS 2018: Delayed initiation of adjuvant chemotherapy significantly impacts survival in women with triple-negative breast cancer

Presenting author Zaida Morante discusses findings showing that the greater the delay in initiating adjuvant chemotherapy the worse a woman’s outcome in terms of overall and disease-free survival (2:59).

SABCS 2018: Low-dose tamoxifen prevents breast intraepithelial neoplasia recurrence

Andrea DeCensi outlines his study findings demonstrating that low-dose tamoxifen 5 mg/day significantly lowers the recurrence of intraepithelial neoplasia versus placebo without increasing endometrial cancer and deep vein thrombosis (3:32).

SABCS 2018: Radiotherapy comparable to axillary lymph node dissection for locoregional control in breast cancer patients with a positive sentinel lymph node

Emiel Rutgers gives an overview of the 10-year follow-up results from the EORTC AMAROS trial demonstrating that radiotherapy has equivalent locoregional control to that of axillary lymph node dissection  but with a reduced risk of lymphedema (4:28).

SABCS 2018: Adjuvant trastuzumab emtansine improves invasive disease-free survival versus trastuzumab after neoadjuvant chemotherapy in HER2-positive women

Charles Geyer reports his phase III study findings showing the potential for adjuvant trastuzumab emtansine as a new standard of care in women with HER-2 positive, early breast cancer and residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy (7:56).

SABCS 2018: Accelerated partial versus whole breast irradiation for controlling ipsilateral breast tumour recurrence

Frank Vicini discusses his research showing that while partial breast irradiation after lumpectomy is not equivalent to whole breast irradiation for long-term control of ipsilateral breast tumour recurrence, the difference is small (2:27).

ASH 2018: Quantum-R trial looks at efficacy of quizartinib in AML patients

Jorge Cortes outlines the findings from the Quantum-R trial of quizartinib in patients with relapsed/refractory acute myeloid leukaemia with a FLT3-internal tandem duplication and a poor prognosis (5:58).

ASH 2018: Two-year follow-up and high-risk subset analysis of ZUMA-1

Frederick Locke discusses long-term follow-up results from the ZUMA-1 trial, demonstrating high rates of durable response to axicabtagene ciloleucel treatment among patients with refractory large B-cell lymphoma (4:18).

ASH 2018: Prophylactic treatment with rivaroxaban reduces cancer patients' VTE risk

Study author Alok Khorana discusses the results of the CASSINI trial, demonstrating a reduction in venous thromboembolism during treatment with rivaroxaban among patients with cancer (2:54).

ASH 2018: BCL2 gene mutation confers resistance to venetoclax treatment in CLL patients

Piers Blombery comments on his study results demonstrating that the BCL2 Gly101Val mutation impairs binding of venetoclax to BCL2, leading to an increased risk of chronic lymphocytic leukaemia progression during treatment (2:56).

ASH 2018: Sustained disease control with tisagenlecleucel in refractory DLBCL setting

Richard Maziarz takes us through the long-term follow-up results of the JULIET trial indicating that the CAR T-cell therapy tisagenlecleucel has achieved a high response rate and enduring responses in adults with relapsed or refractory diffuse large B-cell lymphoma (6:38).

ASH 2018: Reducing chemotherapy in younger diffuse large B-cell lymphoma patients

Viola Poeschel outlines findings from the FLYER trial, showing that a six-cycle R-CHOP plus rituximab regimen can be reduced to four cycles of R-CHOP plus rituximab without compromising efficacy in younger patients with diffuse large B-cell lymphoma and a favourable prognosis (4:33).

ASH 2018: EUTOS long-term survival score recommended over Sokal score for elderly CML patients

Presenting author Fausto Castagnetti discusses the results of their study assessing the best score to predict outcomes in older patients with chronic myeloid leukaemia (4:17).

14-12-2018 | Small-cell lung cancer | News | Article

Veliparib shows efficacy in some patients with extensive-stage SCLC

Some patients with extensive-stage small-cell lung cancer may benefit from the addition of the poly(ADP ribose) polymerase inhibitor veliparib to standard chemotherapy, but further confirmation of its efficacy is needed, say researchers.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.18.00264

13-12-2018 | Breast cancer | News | Article

Trastuzumab emtansine targets residual invasive HER2-positive breast cancer

Adjuvant trastuzumab emtansine halves the risk of invasive disease recurrence or death versus trastuzumab in patients with residual invasive human epidermal growth factor receptor 2-positive early breast cancer, researchers report.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1814017
SABCS 2018; San Antonio, Texas, USA; 4–8 December

10-12-2018 | Lymphoma | News | Article

Long-term data further support axicabtagene ciloleucel use for refractory large B-cell lymphoma

The 2-year follow-up results from the phase I/II ZUMA-1 trial of patients with refractory large B-cell lymphoma show that the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel remains efficacious and manageable in the long term.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30864-7
ASH 2018; San Diego, California, USA; 1–4 December

07-12-2018 | Oncology | News | Article

News in brief

Polycystic ovary syndrome associated with increased cancer risk

Women with polycystic ovary syndrome may have an increased likelihood for developing cancer, although the excess risk appears to be primarily restricted to those who are premenopausal, indicates a population-based study.

Patient-Reported Outcomes Of IMPORT LOW Trial Revealed

Women undergoing whole- or partial-breast radiotherapy after breast conserving surgery can expect a reduction in moderate/marked adverse events over time Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

Twitter Icon Follow medwireNews

Click here
image credits